Tags

Type your tag names separated by a space and hit enter

The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Curr Med Res Opin. 2008 Mar; 24(3):685-94.CM

Abstract

OBJECTIVE

To assess the incremental low-density lipoprotein-cholesterol (LDL-C) lowering efficacy of doubling the statin dose or switching to the ezetimibe/simvastatin 10/20 mg combination tablet (EZE/SIMVA) in patients on simvastatin 20 mg or atorvastatin 10 mg not at LDL-C target < 2.5 mmol/L.

STUDY DESIGN AND METHODS

Patients with documented coronary heart disease (CHD) and/or type 2 diabetes (DM2) with LDL-C > or = 2.5 and < 5.0 mmol/L despite treatment with atorvastatin 10 mg or simvastatin 20 mg were randomized to (1) double statin dose or (2) switch to ezetimibe/simvastatin 10/20, according to a PROBE study design. LDL-C, lipoprotein subfractions and safety data were assessed during the study.

RESULTS

119 of 178 (67%) patients in the EZE/SIMVA group and 49 of 189 (26%) in the doubling statin group reached target LDL-C < 2.5 mmol/L. The odds ratio of success for EZE/SIMVA versus doubling statin treatment in reaching the LDL-C target of < 2.5 mmol/L was 5.7 (95% CI: 3.7-9.0, p < 0.0001). A reduction in total cholesterol (TC), total/high density lipoprotein (HDL) cholesterol ratio and apolipoprotein B was observed in both groups, but this reduction was significantly more pronounced in the EZE/SIMVA group as compared with the doubling statin dose group. Treatment was well tolerated and no difference was observed between the two groups with regard to adverse effects.

CONCLUSIONS

In CHD/DM2 patients treated with simvastatin or atorvastatin with LDL-C persistently > or = 2.5 mmol/L, switching to the EZE/SIMVA was more effective in attaining the LDL-C target of < 2.5 mmol/L than doubling the statin dose.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Roeters van Lennep HW
Oosterscheldeziekenhuizen, Goes, The Netherlands.
Liem AH
No affiliation info available
Dunselman PH
No affiliation info available
Dallinga-Thie GM
No affiliation info available
Zwinderman AH
No affiliation info available
Jukema JW
No affiliation info available

MeSH

AgedAnticholesteremic AgentsAtorvastatinAzetidinesCholesterol, LDLCoronary Artery DiseaseDiabetes Mellitus, Type 2Drug Therapy, CombinationEzetimibeFemaleHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedProspective StudiesPyrrolesSimvastatinTreatment Outcome

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18226326

Clinical Trial Links

Clinical trial which this article describes

Citation

Roeters van Lennep, Henk W O., et al. "The Efficacy of Statin Monotherapy Uptitration Versus Switching to Ezetimibe/simvastatin: Results of the EASEGO Study." Current Medical Research and Opinion, vol. 24, no. 3, 2008, pp. 685-94.
Roeters van Lennep HW, Liem AH, Dunselman PH, et al. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr Med Res Opin. 2008;24(3):685-94.
Roeters van Lennep, H. W., Liem, A. H., Dunselman, P. H., Dallinga-Thie, G. M., Zwinderman, A. H., & Jukema, J. W. (2008). The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Current Medical Research and Opinion, 24(3), 685-94. https://doi.org/10.1185/030079908X273273
Roeters van Lennep HW, et al. The Efficacy of Statin Monotherapy Uptitration Versus Switching to Ezetimibe/simvastatin: Results of the EASEGO Study. Curr Med Res Opin. 2008;24(3):685-94. PubMed PMID: 18226326.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. AU - Roeters van Lennep,Henk W O, AU - Liem,An Ho, AU - Dunselman,Peter H J M, AU - Dallinga-Thie,Geesje M, AU - Zwinderman,Aeilko H, AU - Jukema,J Wouter, Y1 - 2008/01/25/ PY - 2008/1/30/pubmed PY - 2008/6/14/medline PY - 2008/1/30/entrez SP - 685 EP - 94 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 24 IS - 3 N2 - OBJECTIVE: To assess the incremental low-density lipoprotein-cholesterol (LDL-C) lowering efficacy of doubling the statin dose or switching to the ezetimibe/simvastatin 10/20 mg combination tablet (EZE/SIMVA) in patients on simvastatin 20 mg or atorvastatin 10 mg not at LDL-C target < 2.5 mmol/L. STUDY DESIGN AND METHODS: Patients with documented coronary heart disease (CHD) and/or type 2 diabetes (DM2) with LDL-C > or = 2.5 and < 5.0 mmol/L despite treatment with atorvastatin 10 mg or simvastatin 20 mg were randomized to (1) double statin dose or (2) switch to ezetimibe/simvastatin 10/20, according to a PROBE study design. LDL-C, lipoprotein subfractions and safety data were assessed during the study. RESULTS: 119 of 178 (67%) patients in the EZE/SIMVA group and 49 of 189 (26%) in the doubling statin group reached target LDL-C < 2.5 mmol/L. The odds ratio of success for EZE/SIMVA versus doubling statin treatment in reaching the LDL-C target of < 2.5 mmol/L was 5.7 (95% CI: 3.7-9.0, p < 0.0001). A reduction in total cholesterol (TC), total/high density lipoprotein (HDL) cholesterol ratio and apolipoprotein B was observed in both groups, but this reduction was significantly more pronounced in the EZE/SIMVA group as compared with the doubling statin dose group. Treatment was well tolerated and no difference was observed between the two groups with regard to adverse effects. CONCLUSIONS: In CHD/DM2 patients treated with simvastatin or atorvastatin with LDL-C persistently > or = 2.5 mmol/L, switching to the EZE/SIMVA was more effective in attaining the LDL-C target of < 2.5 mmol/L than doubling the statin dose. SN - 1473-4877 UR - https://www.unboundmedicine.com/medline/citation/18226326/The_efficacy_of_statin_monotherapy_uptitration_versus_switching_to_ezetimibe/simvastatin:_results_of_the_EASEGO_study_ DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓13 ↑1]

Related Citations

More